Is Bio-Path Holdings, Inc. (BPTH) a Buy, Sell, or Hold?
OTC : BPTH
Bio-Path Holdings, Inc.
$0.038 USD
-$0.01 (-24.0%)
- Volume
- 40.75K
- Average Volume
- 26.09K
- Market Capitalization
- $355K
- P/E Ratio
- -0.05
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.14
- Year Low
- $0.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.07
Company Overview
OTC
Vikram Paul Grover
Biotechnology
Healthcare
BPTH
1
US
USD
Liquidity Metrics
-0.06
0.07
0.07
0.00
0.00
Sales & Valuation
-$
0.00
-0.04
-1.11
-0.03
Profitability
-$1.1
-$8.67M
0.00%
0.00%
76.46%
-899.85%
P/E Metrics
-0.05
0.00
0.00
Analyst Price Target & Rating
2/5
5 Analysts
%
Financial Health Scores
-304.49
1/9
-$8.47M
$677K
$9.16M
-$5.75M
Key Metrics (TTM)
$872.69K
0.00
-0.15
0.07
76.46%
67.66%
-1630.27%
-85.90%
-25102 days
Company Executives
| Name | Title |
|---|---|
| Douglas Morris | Co-Founder, Director of Investor Relations & Secretary |
| Anthony Price | Senior Vice President of Finance, Accounting & Administration |
| Michael Hickey | Member of Scientific Advisory Board & VP of Clinical Operations |
| Vikram Paul Grover | President, Chief Executive Officer, Chief Financial Officer & Director |
| Ana Tari Ashizawa | Senior Vice President of Research, Development & Clinical Design |
Poll Results
No votes yet today — be the first to share your view!
About Bio-Path Holdings, Inc. (OTC:BPTH) Stock
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is ... in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.
Frequently Asked Questions
-
What is the current Bio-Path Holdings, Inc. (BPTH) stock price?
-
Bio-Path Holdings, Inc.(OTC:BPTH) stock price is $0.038 in the last trading session. During the trading session, BPTH stock reached the peak price of $0.14 while $0.01 was the lowest point it dropped to. The percentage change in BPTH stock occurred in the recent session was --24.0% while the dollar amount for the price change in BPTH stock was -$0.01.
-
BPTH's industry and sector of operation?
-
The OTC listed BPTH is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BPTH?
-
Douglas Morris | Co-Founder, Director of Investor Relations & Secretary
Anthony Price | Senior Vice President of Finance, Accounting & Administration
Michael Hickey | Member of Scientific Advisory Board & VP of Clinical Operations
Vikram Paul Grover | President, Chief Executive Officer, Chief Financial Officer & Director
Ana Tari Ashizawa | Senior Vice President of Research, Development & Clinical Design -
How many employees does BPTH have?
-
Number of BPTH employees currently stands at 1. BPTH operates from 4710 Bellaire Boulevard, Bellaire, TX 77401, US.
-
Link for BPTH official website?
-
Official Website of BPTH is: https://www.biopathholdings.com
-
How do I contact BPTH?
-
BPTH could be contacted at phone #832 742 1357 and can also be accessed through its website. BPTH operates from 4710 Bellaire Boulevard, Bellaire, TX 77401, US.
-
How many shares of BPTH are traded daily?
-
The average number of BPTH shares traded daily for last 3 months was 26.09K.
-
What is the market cap of BPTH currently?
-
The market value of BPTH currently stands at $355K with its latest stock price at $0.038